Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
Top lawyer highlights concerns raised by expected growth in gene editing sector. Earlier this year, a major US financial analyst firm identified Longevity as one...
Making progress and currently fundraising: "The world’s first epigenetic platform for health measure discovery." While questions have recently been raised around the validity of direct-to-consumer...
AgeX and Juvenescence publish progress in development of hypoimmunogenic cells. Longevity focused life sciences companies, AgeX Therapeutics and Juvenescence , today announced the publication...